Alto Neuroscience, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-38.4M | $48.3M |
| FY2023 | $9.9M | $-71.7M | $82.5M |
| FY2024 | $10.3M | $151.5M | $168.2M |
| FY2025 | $16.2M | $151.1M | $176.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-38.4M | $48.3M |
| FY2023 | $9.9M | $-71.7M | $82.5M |
| FY2024 | $10.3M | $151.5M | $168.2M |
| FY2025 | $16.2M | $151.1M | $176.5M |